Gene polymorphism rapid detection kit for predicting bleeding transformation risk after rt-PA treatment and application
By simultaneously detecting polymorphic sites of A2M, FXII and ZBTB46 genes in a single tube, a fluorescence probe method combined with melting curve method was used to construct a risk assessment model for bleeding conversion, and the low flux and non-specific amplification in the prior art were solved. The problem has achieved rapid and accurate risk assessment of bleeding conversion after rt-PA treatment, and promoted the application of personalized medication.
Patent Information
- Application Number
- CN202411249545.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-12-03
AI Technical Summary
The existing genetic polymorphism detection methods have high cost, cumbersome steps, low detection throughput and nonspecific amplification to cause false positive and false negative problems, which are difficult to promote clinically and application.
A rapid detection kit for gene polymorphism predicting the risk of bleeding conversion after rt-PA treatment was provided. The fluorescent probe method combined with fluorescent probe melting curve method was used to simultaneously detect three genes A2M rs669, FXII rs1801020 and ZBTB46 rs76484331 in a single tube. Polymorphic loci and internal reference genes were constructed through the Logit(P) formula to construct a bleeding conversion risk assessment model, simplifying operations and improving detection accuracy.
Achieve rapid, accurate, low-cost, and high specificity multi-gene detection, reduces equipment requirements and detection time, improves detection accuracy, and can effectively predict the risk of bleeding conversion after rt-PA treatment in clinical practice, helping doctors to do it. Make personalized drug use decisions.
Smart Images

Figure CN119061133A_ABST
Abstract
Description
Technical Field
[0001] The present invention is applied to the technical field of gene detection, and specifically relates to a gene polymorphism rapid detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment and an application thereof. Background Art
[0002] Worldwide, stroke has become the second most common cause of death and the first most common cause of disability among adults. There are many causes of stroke, among which hypertension, diabetes, hyperlipidemia and other factors can cause damage to vascular endothelial cells. Patients with atrial fibrillation and heart valve replacement will also cause changes in blood flow status. Hereditary and acquired hypercoagulation can cause platelet aggregation and the formation of fibrin and platelet complexes, forming thrombi and causing stroke. Intravenous thrombolysis is currently one of the most important measures to restore cerebral blood flow in patients with acute ischemic stroke (AIS). The "Guidelines for Intravenous Thrombolysis for Acute Ischemic Stroke in China (2021)" recommends intravenous thrombolysis: Patients with acute ischemic stroke within 4.5 hours of onset should be screened according to indications and contraindications, and given intravenous rt-PA thrombolysis as soon as possible. Recombinant tissue plasminogen activator (rt-PA) is a serine protease that converts inactive precursor plasminogen into plasmin. It is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of AIS and is the most commonly used thrombolytic agent today. However, a large number of studies have shown that side effects may occur after rt-PA treatment, and the risk of cerebral hemorrhage increases by 6-7 times, which restricts the application of rt-PA. The most serious manifestation of cerebral hemorrhage is parenchymal hematoma (PH), also known as hemorrhagic transformations (HT), which can lead to neurological deterioration, disability and death, and increase the patient's 3-month mortality risk by 2.4 to 4.5 times. This is also the main concern of many primary hospitals for not wanting to carry out thrombolytic therapy. If patients can be better individualized and the risk of hemorrhagic transformation can be reduced, it will be beneficial to expand the population that benefits from intravenous thrombolytic therapy.
[0003] Studies have shown that gene polymorphisms are associated with the efficacy and safety of rt-PA. ZBTB46 is expressed in brain tissue through neurons and endothelial cells. Carrera, Caty et al. found through GWAS that the ZBTB46 gene was associated with the formation of solid hematomas after rt-PA treatment in the Spanish population. The polymorphic site rs76484331 located in ZBTB46 interacted with the promoter site located at 20q13, causing a higher risk of hemorrhagic transformation after rt-PA treatment. In addition, Del Rio-Espinola et al. found through association studies that a polymorphism (rs669) in alpha-2-macroglobulin (A2M) and a polymorphism (rs1801020) from the FXII gene were associated with hemorrhagic transformation after rt-PA treatment in the Spanish population. Due to differences in genetic backgrounds among different ethnic groups, the incidence of bleeding in China is higher than that in Western populations. Current studies are based on fewer Chinese Han populations, so it is still necessary to screen gene polymorphic sites suitable for predicting hemorrhagic transformation in the Chinese Han population. The predictive score for the occurrence of hemorrhagic transformation after rt-PA treatment may help identify patients at high or low risk of bleeding complications to help physicians make decisions to avoid treatment delays, adjust rt-PA doses, initiate mechanical clot removal alone, or implement additional support or treatment.
[0004] The main methods for detecting gene polymorphism (SNP) typing include Sanger sequencing, fluorescent probe method, PCR melting curve method, PCR-RFLP, PCR-capillary electrophoresis method, gene chip method, time-of-flight mass spectrometry, ARMS-PCR method, etc. These methods either rely on large-scale precision instruments and equipment, are costly, have complicated steps and take a long time, and are difficult to promote in clinical practice; or have low detection throughput, and generally only one SNP site can be detected in one reaction. Clinically, predicting adverse drug reactions and drug efficacy often requires simultaneous detection of multiple sites. Multiplex PCR technology is often used to detect multiple sites at the same time. At present, there are some kits based on PCR melting curve method or multiplex fluorescent PCR probe method on the market, but they are usually suitable for detecting viruses, bacteria, gene mutations, etc.; and drug-related genotyping, if it is to clarify drug efficacy and adverse reactions, must accurately identify different genotypes such as wild, heterozygous mutations, and homozygous mutations, which means that more primers and probes are needed to detect genes, and the more detection multiples, the more non-specific amplification will occur, resulting in false positives and / or false negatives, affecting the accuracy of detection. Conventional multiplex fluorescent PCR probe method can only detect polymorphism of one gene locus with two fluorescent channels, and existing PCR instruments can only detect fluorescent signals emitted by 4 to 6 fluorescent groups. Conventional multiplex PCR melting curve method is also prone to the situation that Tm value differences cannot distinguish gene loci. Therefore, it is necessary to develop a simple, fast, accurate, low-cost, high-specificity kit that can identify multiple SNP locus genotypes in a single tube and predict the risk of hemorrhagic transformation after rt-PA in the Chinese Han population, which is suitable for clinical promotion and popularization, and provides a reference for personalized rt-PA medication. Summary of the invention
[0005] The present invention provides a gene polymorphism rapid detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment and its application, which can detect three gene polymorphism sites and one internal reference gene in a single tube at the same time, and effectively predict the hemorrhagic transformation after rt-PA treatment. The kit of the present invention has the characteristics of multiple detection, simple operation, short detection cycle, low cost, high accuracy, high specificity, and is conducive to clinical promotion and use, and assists doctors in selecting rt-PA medication regimens that are more suitable for the Chinese Han population.
[0006] The present invention solves the technical problem by adopting the following technical solutions:
[0007] The first object of the present invention is to provide a kit for use in establishing a risk assessment model for predicting hemorrhagic transformation of acute ischemic stroke by rt-PA thrombolysis, wherein the kit amplifies three gene site polymorphisms of A2M rs669, FXIIrs1801020 and ZBTB46 rs76484331 and an internal reference gene in the same closed reaction tube, and the risk assessment model is constructed in the following manner: according to the admission NIHSS score and the genotyping of A2M, FXII and ZBTB46, the risk score Logit (P) of "whether hemorrhagic transformation occurs" is predicted;
[0008] Logit (P) = -3.68 + 1.92 × A2M rs669 (AA or AG = 1, GG = 0) + 0.3 × FXII rs1801020 (AG or GG = 1, AA = 0) + 1.88 × ZBTB46 rs76484331 (GT or TT = 1, GG = 0) + 1.3 × admission NIHSS score;
[0009] Then according to the formula: P = e Logit(P) / (1+e Logit(P) ), the probability of hemorrhagic transformation of AIS patients treated with rt-PA thrombolytic therapy was calculated; if P>0.289, the patient was at high risk of hemorrhagic transformation and needed to reduce the dosage of rt-PA or switch to other thrombolytic drugs; if P<0.289, the patient was at low risk of hemorrhagic transformation and should be given the standard dose.
[0010] Furthermore, the risk assessment model is constructed by the following steps:
[0011] (1) Sample collection: Oral mucosal exfoliated cells from patients with acute ischemic stroke who require rt-PA thrombolytic therapy were scraped with disposable sterile swabs as samples to be tested;
[0012] (2) Genetic testing: Add the sample to be tested into the PCR tube containing the reaction solution in the kit, set up a positive control group and a negative control group for testing, collect FAM and TexasRed fluorescence signals, and set up the PCR reaction program for amplification reaction;
[0013] (3) Result interpretation: After the PCR amplification reaction is completed, the result is judged based on the collected fluorescence signal amplification curve and melting peak Tm value; when the positive control group has FAM and TexasRed fluorescence amplification curves and corresponding melting peaks, the negative control group has no amplification curve and melting peak, the test sample has an amplification curve and melting peak, and the internal reference gene signal of the TexasRed channel has an obvious melting peak signal at 73℃±1℃, the experiment is judged to be successful, and the A2M rs669, FXII rs1801020 and ZBTB46rs76484331 gene loci are typed; if not, re-testing is required;
[0014] (4) Construction of a hemorrhagic transformation risk assessment model: For each AIS patient, the risk score Logit (P) of "whether hemorrhagic transformation will occur" is predicted based on the admission NIHSS score and the genotyping of A2M, FXII, and ZBTB46:
[0015] Logit (P) = -3.68 + 1.92 × A2M rs669 (A allele = 1, G allele = 0) + 0.3 × FXIIrs1801020 (G allele = 1, A allele = 0) + 1.88 × ZBTB46 rs76484331 (T allele = 1, G allele = 0) + 1.3 × admission NIHSS score; then according to the formula: P = e Logit(P) / (1+e Logit(P) ), the probability of hemorrhagic transformation of AIS patients treated with rt-PA thrombolytic therapy was calculated; if P>0.289, the patient was at high risk of hemorrhagic transformation and needed to reduce the dosage of rt-PA or switch to other thrombolytic drugs; if P<0.289, the patient was at low risk of hemorrhagic transformation and should be given the standard dose.
[0016] The reaction conditions of the PCR reaction system in step (2) are:
[0017]
[0018]
[0019] The second object of the present invention is to provide a gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment, the kit is used for jointly detecting the polymorphisms of three gene sites A2M rs669, FXII rs1801020 and ZBTB46rs76484331 and an internal reference gene in the same closed reaction tube, the kit comprises a primer set sequence, the primer set sequence comprises a total of 8 primer sequences, 2 Taqman fluorescent probes, 5 3'-end blocked media probes and 2 fluorescently labeled media sequences; the primer set sequence is as follows:
[0020] Primer set sequences for detecting A2M rs669:
[0021] Upstream primer: 5'-CCAGTGTTGAGATAGCCAAT-3', as shown in SEQ ID No. 1;
[0022] Downstream primer: 5'-GCTGTGGAGAGCAGAATATG-3', as shown in SEQ ID No. 2;
[0023] Wild-type Taqman probe: 5'-FAM-ACTCCAGAGATCA-MGB modified-3', shown in SEQ ID No. 3;
[0024] Mutant Taqman probe: 5'-TexasRed-ACTCCAGAGGTCA-MGB modified-3', shown in SEQ ID No. 4;
[0025] Primer set sequences for detecting FXII rs1801020:
[0026] Upstream primer: 5'-AAAGTGTTGACTCCAAGCTC-3', shown in SEQ ID No.5;
[0027] Downstream primer: 5'-GATCTGGACTCCTGGATAGG-3', shown in SEQ ID No.6;
[0028] Wild-type mediator probe: 5'- GGGAGAAGTGTCAC AGAGCCCTCATGGCATCC-dideoxy modification-3', shown in SEQ ID No.7;
[0029] Mutation-mediated probe: 5'- GTGGGGAGAAGT AGAGCCCTCATGGCGTCC-dideoxy modification-3', shown in SEQ ID No. 8;
[0030] Primer set sequences for detecting ZBTB46 rs76484331:
[0031] Upstream primer: 5'-GAACAGAATCCCACATACGG-3', shown in SEQ ID No.9;
[0032] Downstream primer: 5'-TTCTTCAAGCGTGAGGGATG-3', shown in SEQ ID No.10;
[0033] Wild-type mediator probe: 5'- AGATCGTGAGGGCCACAGTGTA+GGTCATTTAACC-dideoxy modification-3', as shown in SEQ ID No.11;
[0034] Mutation-mediated probe: 5'- GAAGAGATCGTGAGCCA CAGTGTATGTCATTTAACCG-dideoxy modification-3', shown in SEQ ID No.12;
[0035] The sequences of the internal reference β-actin primer probe are as follows:
[0036] Upstream primer: 5'-ACCAGATGTGTTCCGTGTCC-3', as shown in SEQ ID No. 13;
[0037] Downstream primer: 5'-TGCTCGTGTTCATCAAAGTCT-3', as shown in SEQ ID No. 14;
[0038] Intermediate probe: 5'- CACAGGAAGAGATCG CCTTCGTGCTTGTGATGTCTTC—dideoxy modification-3′, as shown in SEQ ID No.15.
[0039] Furthermore, the kit simultaneously uses a fluorescent probe method combined with a fluorescent probe melting curve method to detect the level of hemorrhagic transformation in the sample.
[0040] Furthermore, the A2M rs669 gene locus was detected by the Taqman fluorescent probe method, and the FXII rs1801020, ZBTB46rs76484331 and β-actin internal reference gene loci were detected by the fluorescent probe melting curve method.
[0041] The kit uses a fluorescent probe method combined with a fluorescent probe melting curve method to simultaneously detect three gene polymorphism sites, A2Mrs669, FXII rs1801020 and ZBTB46 rs76484331, and an internal reference gene in a closed reaction tube, and can accurately distinguish the wild genotype, heterozygous mutant genotype, and homozygous mutant genotype of the gene locus.
[0042] Furthermore, the two mediator sequences are two mediator primer docking sequences for mediator probe binding, and their sequences are:
[0043] SStarget-Probe1:
[0044] 5'-FAM-ACCAGAGATACCTTGACACTTCTCCCACTCTGGT-BHQ1 modified-3', as shown in SEQ ID No. 16;
[0045] SStarget-Probe2:
[0046] 5′-TexasRed-ACGAGCTGCCCTCACGATCTCTTCCTGTGAGCTCGT–BHQ2-3′, as shown in SEQ ID No.17.
[0047] Furthermore, the detection of FXII rs1801020 introduces the intermediate primer docking sequence SStarget-Probe1; the detection of ZBTB46rs76484331 and β-actin internal reference gene introduces the intermediate primer docking sequence SStarget-Probe2.
[0048] The media sequence is a sequence with a stem-loop structure and is not paired with the sequence of the gene to be tested. Any segment in the middle is selected as the complementary pairing sequence of the media primer. The melting curve analysis of the complementary sequences of different lengths of media primers after PCR amplification shows different melting point Tm values. The sequence design can be used to make the melting peak Tm of the typing differ by 5°C or more, thereby realizing SNP typing of multiple genes to be tested in the same fluorescent labeling channel.
[0049] Furthermore, the fluorescent group at the 5' end of the Taqman probe is a FAM or TexasRed group, and the quenching group at the 3' end is a MGB modification group.
[0050] Furthermore, the 5' end of the mediator probe is connected to a mediator primer sequence that is complementary to any segment in the middle of the mediator sequence, including a mediator primer sequence for PCR amplification and a complementary sequence of the gene site to be detected. The underlined sequence is the mediator primer for PCR amplification; the non-underlined sequence at the 3' end is the complementary sequence of the gene site to be detected, and the 3' end is modified with dideoxy.
[0051] Furthermore, the 23rd base of the ZBTB46 rs76484331 wild-type mediator probe is modified by LNA, which is an oligonucleotide derivative that can reduce the probe length, improve the probe specificity, and enhance the ability to identify SNPs.
[0052] Furthermore, the fluorescent group at the 5' end of the mediator sequence is a FAM or TexasRed group, and the quenching group at the 3' end is a BHQ1 or BHQ2 modification group.
[0053] Furthermore, the kit also includes a PCR reaction solution, a positive quality control product and a negative quality control product.
[0054] Furthermore, the PCR reaction solution includes PCR buffer, dNTPs, MgCl2, Taq enzyme, sodium dodecyl sulfate, polyethylene glycol octylphenyl ether, a primer set and ultrapure water.
[0055] Furthermore, the working concentrations of the three gene locus primers are 0.4-0.7 μM.
[0056] Furthermore, the working concentration of the internal reference gene primer is 0.15-0.3 μM.
[0057] Furthermore, the working concentrations of the three gene locus mediator probes are 0.1-0.2 μM.
[0058] Furthermore, the working concentration of the internal reference gene mediator probe is 0.05-0.1 μM.
[0059] Furthermore, the working concentration of the mediator sequence is 0.05-0.15 μM.
[0060] Furthermore, the concentration of each component in the PCR reaction solution is as follows:
[0061]
[0062]
[0063] Furthermore, the positive quality control product is a mixed solution of recombinant pUC57 clone plasmids containing A2M rs669, FXII rs1801020, ZBTB46rs76484331 wild-type and mutant recombinant plasmids and β-actin.
[0064] Furthermore, the recombinant pUC57 cloning plasmid is synthesized by selecting a 200 bp sequence near the SNP site, which is connected to a pUC57 vector and then transformed into a TOP10 bacterial cell for cloning to obtain a plasmid.
[0065] Furthermore, the negative control product is a pUC57 empty plasmid that does not contain the gene to be detected and β-actin.
[0066] Compared with the prior art, the present invention has the following beneficial effects:
[0067] (1) The present invention adopts a fluorescent probe method combined with a fluorescent melting curve method to detect gene polymorphisms. A single tube can simultaneously detect three gene polymorphism sites and an internal reference gene, overcoming the difficulties in the prior art that single-tube detection of multiple SNP sites requires multiple fluorescent channels for gene typing or that the difference in melting peak Tm values of the conventional fluorescent probe melting curve method is small, thereby achieving high-throughput detection, reducing the number of PCR instrument detection channels, reducing detection costs, and saving samples; rigorous selection and combination of primer probe design in the early stage makes the melting peak Tm of typing differ by 5°C or more, reducing the temperature precision requirements, thereby reducing the equipment requirements for high throughput.
[0068] (2) The present invention has a short detection cycle, and the detection can be completed within 2 hours. Patients with acute ischemic stroke require intravenous rt-PA thrombolytic therapy within 4.5 hours of onset. The present invention overcomes the cumbersome and time-consuming steps of extracting DNA to detect gene polymorphisms in the prior art, and uses disposable sterile swabs to scrape the patient's oral mucosal exfoliated cells as samples to be tested, which can quickly detect the three gene polymorphisms of ZBTB46, A2M and FXII related to hemorrhagic transformation after rt-PA treatment. The kit of the present invention has the characteristics of high sensitivity, simple operation, good specificity, etc. The entire reaction process is closed to reduce pollution, the accuracy rate reaches more than 99%, the results are easy to judge, and it is not limited to professionals or high-precision instruments, which is conducive to promotion and use in grassroots units.
[0069] (3) The present invention provides a model and construction method for predicting the risk of hemorrhagic transformation after rt-PA treatment. The model is based on a cohort study of the Han Chinese population and is composed of four factors: A2M rs669, FXII rs1801020, and ZBTB46 rs76484331 gene loci typing and admission NIHSS score. The risk score Logit (P) for predicting "whether hemorrhagic transformation occurs" is:
[0070] Logit (P) = -3.68 + 1.92 × A2M rs669 (AA or AG = 1, GG = 0) + 0.3 × FXII rs1801020 (AG or GG = 1, AA = 0) + 1.88 × ZBTB46 rs76484331 (GT or TT = 1, GG = 0) + 1.3 × admission NIHSS score. According to the formula: P = e Logit(P) / (1+e Logit(P) ), and the probability of hemorrhagic transformation of AIS patients treated with rt-PA thrombolytic therapy was calculated.
[0071] (4) The present invention provides rt-PA medication recommendations suitable for the Chinese Han population. The patient characteristic curve (AUC-ROC) is generated based on the prediction model, and the cut-off value for distinguishing and evaluating whether hemorrhagic transformation occurs is determined to be 0.289. P>0.289 indicates a high-risk population for hemorrhagic transformation, and it is recommended to reduce the dosage of rt-PA or replace it with other thrombolytic drugs; P<0.289 indicates a low-risk population for hemorrhagic transformation, and the drug is administered according to the standard dose. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 It is a diagram showing the analysis and detection principle of the fluorescent PCR probe method and the fluorescent probe melting curve method of the present invention.
[0073] Figure 2 This is the patient characteristic curve (AUC-ROC) based on the prediction model in Example 1 of the present invention.
[0074] Figure 3 This is a new model decision curve analysis diagram in Example 1 of the present invention.
[0075] Figure 4 These are the A2M, FXII and ZBTB46 gene polymorphism detection results of the P1 sample in Example 6 of the present invention.
[0076] Figure 5 These are the A2M, FXII and ZBTB46 gene polymorphism detection results of the P2 sample in Example 6 of the present invention. DETAILED DESCRIPTION
[0077] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments. It should be understood that the following embodiments are only exemplary illustrations and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope of protection that the present invention is intended to protect.
[0078] In addition, unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0079] It should be noted that the detection principle involved in this kit is: first, query the sequence information of A2M rs669, FXII rs1801020 and ZBTB46 rs76484331 gene loci on the NCBI online database website (https: / / www.ncbi.nlm.nih.gov), and select the 200bp sequence around the SNP site for specific primer and probe design. In order to achieve simultaneous detection of fluorescent probe PCR reaction and fluorescent probe melting curve, one of the sites uses the conventional Taqman fluorescent probe method. The other sites use the fluorescent probe melting curve method, and the intermediate probe is designed, such as Figure 1The P2 sequence shown is a sequence that specifically binds to the SNP site of the target gene to be detected. A mediator primer P1 is connected to P2, and the primer mediator sequence is a sequence with a stem-loop structure. The sequence is unrelated to the target gene to be detected, and P1 can be complementary to a sequence in the middle of the mediator sequence. During PCR amplification, when the Taq enzyme encounters a fluorescent probe bound to the template, its 3'→5' exonuclease activity will cut off the probe, so that the reporter group is away from the quencher group, thereby releasing the fluorescent signal; at the same time, the Taq enzyme cuts P1 from the mediator probe, and the 3' end of the mediator probe is modified with a dideoxygenase, which blocks the probe and prevents the extension reaction of the probe. When the melting curve reacts, as the temperature rises, the stem-loop structure of the mediator sequence opens as P1 is extended, and the fluorescent group and the quencher group are separated, thereby releasing the fluorescent signal. The melting peak Tm value is obtained after the melting curve analysis. Different melting peak Tm values are obtained by carefully designing base sequences of different lengths of P1, thereby realizing the distinction between wild types and mutant types of different gene sites.
[0080] It should be noted that, in the present invention, NIHSS (National Institute of Health stroke scale) refers to the National Institutes of Health stroke scale of the United States, which evaluates the main clinical manifestations after cerebrovascular disease and includes 11 dimensions, namely consciousness, gaze, visual field, facial paralysis, movement (upper limbs, lower limbs), ataxia, sensation, language, dysarthria, and neglect.
[0081] Example 1 Construction of a model for predicting the risk of hemorrhagic transformation after intravenous thrombolytic therapy with rt-PA
[0082] 1. Sample collection
[0083] Patients aged over 18 years, who were diagnosed with AIS according to the "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018" and received standard-dose rt-PA intravenous thrombolysis within 4.5 hours were selected as the research subjects. Exclusion criteria: patients with cerebral hemorrhage confirmed by CT or MRI, patients with cerebral infarction caused by subarachnoid hemorrhage and sinus vein thrombosis; patients with severe systemic diseases and patients who had received anticoagulant drugs within 48 hours. In order to reduce the impact of population stratification, all patients were Han Chinese, with no blood relationship or intermarriage history. All patients treated with rt-PA intravenous thrombolysis were evaluated for the occurrence of hemorrhagic transformation by CT or MR scan after 24 hours, and were classified according to the European Collaborative Acute Stroke Study (ECASSⅢ) criteria into a non-hemorrhagic transformation group and a hemorrhagic transformation group. A total of 543 patients were included in this retrospective analysis and randomly divided into a training set (325 cases) and a validation set (218 cases). The training set included 244 patients without hemorrhagic transformation and 81 patients with hemorrhagic transformation, and the validation set included 171 patients without hemorrhagic transformation and 47 patients with hemorrhagic transformation.
[0084] 2. Statistical analysis
[0085] SPSS 23.0 software was used for data analysis. The data were expressed as cases (%), and the inter-group comparison was performed using the independent sample t test. The count data were expressed as cases (%), and the inter-group comparison was performed using the chi-square test or Fisher's exact probability method. The items with statistically significant differences (p < 0.05) in the univariate analysis were selected as independent variables, and the selected influencing factors were analyzed by multivariate logistic regression to construct a prediction model for hemorrhagic transformation after rt-PA treatment. The patient operating characteristic curve (AUC-ROC) was drawn using R language and the decision curve was applied to evaluate the predictive ability and clinical applicability of the model. The closer the AUC is to 1, the better the discrimination of the model.
[0086] 3. General clinical data
[0087] There were no significant differences in gender, age, body mass index, time from onset to thrombolysis, NIHSS score at admission, and past medical history (hypertension, diabetes, hyperlipidemia, and heart disease) between the training set and the validation set (P>0.05). There were no significant differences in gender, age, body mass index, time from onset to thrombolysis, and whether or not patients had diabetes, hypertension, and hyperlipidemia between the non-hemorrhagic transformation group and the hemorrhagic transformation group (p>0.05); the NIHSS score at admission in the hemorrhagic transformation group was significantly higher than that in the non-hemorrhagic transformation group (p<0.05).
[0088] Table 1. Comparison of general clinical data of patients in the two groups of training sets
[0089]
[0090]
[0091] 4. Correlation between hemorrhagic transformation and genotype
[0092] All collected patient samples were subjected to genotyping tests, and according to the test results, the correlation between hemorrhagic transformation and genotype in the training set is shown in Table 2. The three loci A2M rs669, FXII rs1801020, and ZBTB46 rs76484331 were significantly correlated with hemorrhagic transformation after rt-PA intravenous thrombolysis (P<0.05).
[0093] Table 2. Genotype distribution of two groups of patients in the training set
[0094]
[0095] 5. Construction of a prediction model for hemorrhagic transformation
[0096] The above-mentioned independent factors with significant correlation with hemorrhagic transformation were included in the multivariate Logistic regression analysis. The results are shown in Table 3. A2M, FXII, ZBTB46 gene polymorphisms and admission NIHSS score were statistically associated with the occurrence of hemorrhagic transformation (P<0.05). The risk of hemorrhagic transformation in A2M rs669 locus A allele carriers was 6.84 (95% CI: 2.14-21.84) times that of G allele carriers. The risk of hemorrhagic transformation in FXII rs1801020 locus G allele carriers was 1.35 (95% CI: 0.73-2.52) times that of A allele carriers. The risk of hemorrhagic transformation in carriers of the T allele of rs76484331 locus is 6.56 (95% CI: 2.57-16.71) times that of the G allele, and the risk of hemorrhagic transformation in patients with an admission NIHSS score of 15 or more is 3.66 (95% CI: 2.07-6.48) times that of patients with a score less than 15. Based on this, the risk score Logit (P) of "whether hemorrhagic transformation occurs" can be predicted for each AIS patient based on the admission NIHSS score and the genotyping of A2M, FXII, and ZBTB46:
[0097] Logit (P) = -3.68 + 1.92 × A2M rs669 (AA or AG = 1, GG = 0) + 0.3 × FXII rs1801020 (AG or GG = 1, AA = 0) + 1.88 × ZBTB46 rs76484331 (GT or TT = 1, GG = 0) + 1.3 × admission NIHSS score. Then in the actual application of the model, the formula can be used: P = e Logit(P) / (1+e Logit(P)), and the probability of hemorrhagic transformation of AIS patients treated with rt-PA thrombolytic therapy was calculated.
[0098] Table 3. Multivariate Logistic regression analysis
[0099]
[0100] See attached Figure 2 , 3 The discrimination of the new model was verified by the ROC curve. The area under the ROC curve (AUC) of the training set was 0.73 (0.67-0.80), and the cut-off value was 0.289; the area under the ROC curve (AUC) of the validation set was 0.75 (0.67-0.83), and the cut-off value was 0.289. The calibration of the new model was verified by the Hosmer-Lemeshow test of the training set. 2 =1.523, p=0.823, validation set Hosmer-Lemeshow test χ 2 =2.896, p=0.575, indicating that the prediction model is good. The results of decision curve analysis showed that when the threshold probability values of the training set and the validation set were between 0.1 and 0.8, the model had more net benefits compared with all AIS patients who received rt-PA intravenous thrombolysis and had hemorrhagic transformation or all AIS patients who did not receive rt-PA thrombolysis and had no hemorrhagic transformation. According to the cut-off value, whether hemorrhagic transformation occurred or not, the probability value P>0.289 was a high-risk group for hemorrhagic transformation, and P<0.289 was a low-risk group for hemorrhagic transformation.
[0101] Method for using the kit of the present invention to predict the risk of hemorrhagic transformation after rt-PA intravenous thrombolytic therapy:
[0102] Taking a patient with hemorrhagic transformation in the validation set as an example, the clinical characteristics and follow-up data of the patient showed that the NIHSS score upon admission was 16 points, and the A2M, FXII, and ZBTB46 gene detection results measured by the kit of the present invention were AG, AA, and GG, respectively. The risk score of "whether hemorrhagic transformation occurs" was calculated according to the constructed prediction model: Logit (P) = -3.68 + 1.92 × 1 + 0.3 × 0 + 1.88 × 0 + 1.3 × 16 = 19.04. Then, P = e Logit(P) / (1+e Logit(P) ), the probability of hemorrhagic transformation of AIS patients treated with rt-PA thrombolysis was calculated to be P = 0.746. The probability value P > 0.289 indicates a high risk of hemorrhagic transformation.
[0103] Example 2: Design and use of primer and probe combinations
[0104] The primer and probe combinations for detecting the three gene polymorphism sites of ZBTB46, A2M and FXII are shown in Table 4:
[0105] Table 4 Primer probe sequence list
[0106]
[0107] Example 3: Acquisition of quality control products
[0108] The method for obtaining positive quality control products is as follows: according to the queried SNP sequence information, the 200bp sequence around the SNP site is selected for synthesis, connected to the pUC57 vector and transformed into TOP10 bacteria for cloning, and finally the plasmid is obtained after extraction and purification. The wild-type plasmids, mutant plasmids and β-actin plasmids of A2M rs669, FXII rs1801020, ZBTB46 rs76484331 obtained were diluted to 3.0×10 6 The positive control product was obtained by mixing 100 μL of ...
[0109] Example 4: Configuration of PCR reaction solution
[0110] The present invention realizes the simultaneous detection of real-time fluorescent PCR reaction and melting curve.
[0111] The detection of the two alleles of FXII rs1801020 and ZBTB46 rs76484331 and the β-actin internal reference gene in this kit requires the introduction of a mediator sequence, and the detection is performed using a fluorescent probe melting curve method. The kit of the present invention includes 24 reaction tubes, 1 negative quality control product, and 1 positive quality control product. The concentration of the reaction solution is shown in Table 5.
[0112] Table 5 PCR reaction solution
[0113] Reaction solution components concentration 4×OmniIIIBuffer 1.0~1.2× dNTPs(10mM) 0.1~0.3mM <![CDATA[MgCl2(100mM)]]> 4.0~6.0mM Sodium Lauryl Sulfate 0.00064%w / v Polyethylene glycol octylphenyl ether 0.00013%w / v A2Mrs669 upstream primer 0.4~0.7μM A2Mrs669 downstream primer 0.4~0.7μM A2Mrs669 wild-type Taqman probe 0.1~0.2μM A2Mrs669 mutant Taqman probe 0.1~0.2μM FXIIrs1801020 upstream primer 0.4~0.7μM FXIIrs1801020 downstream primers 0.4~0.7μM FXIIrs1801020 wild-type vector probe 0.1~0.2μM FXIIrs1801020 mutant mediator probe 0.1~0.2μM SStarget-Probe1 0.05~0.15μM ZBTB46rs76484331 upstream primer 0.4~0.7μM ZBTB46rs76484331 downstream primers 0.4~0.7μM ZBTB46rs76484331 wild-type vector 0.1~0.2μM ZBTB46rs76484331 mutant mediator probe 0.1~0.2μM β-actin upstream primer 0.15~0.3μM β-actin downstream primers 0.15~0.3μM β-actin mediator probe 0.05~0.1μM SStarget-Probe2 0.05~0.15μM RobustartTaq 0.105–0.15 U / μL Ultrapure water Add to 23 μL
[0114] During the PCR amplification process, the Taqman fluorescent probe is hydrolyzed to release the fluorescent signal. In the melting curve stage, the Taqman fluorescent probe must be consumed, otherwise it will interfere with the melting curve results of the same fluorescent channel; in addition, during the annealing extension process, the cut P1 will also combine with the media sequence, resulting in too high a fluorescent background signal, causing a false positive or false negative. Therefore, it is necessary to reasonably coordinate the proportional relationship between each primer probe, the Taqman fluorescent probe cannot be excessive, and the media sequence concentration cannot be too high to affect the amplification curve. The present invention performs a series of screening on primers and probes, and performs a series of optimizations on the dosage ratio of primers and probe concentrations, the reaction concentration of each component, and the PCR reaction procedure to ensure the specificity, accuracy and sensitivity of the PCR reaction amplification.
[0115] Example 5: Use of Gene Detection Kit
[0116] 1. Sample collection
[0117] Before sampling, the patient must rinse his mouth with clean water twice, each time for no less than 5 seconds, and swallow 2-3 times after rinsing his mouth, trying to avoid residual saliva on the inner wall of the mouth. The sampler must wear gloves and masks. In this embodiment, the cheek wall cells in the patient's mouth are collected, and a disposable sterile swab and a reaction solution are taken out from the swab packaging bag, and the swab end cap is removed. During this process, be careful not to touch the reagent plug, so that the swab end is nearly 90° in contact with the cheek wall in the mouth, and evenly scrape 5 times (up and down is 1 time), and the strength is preferably slightly protruding from the cheeks; after sampling, the swab is immediately inserted into the reaction solution and covered with the reagent plug, and the machine is tested. Patients should avoid eating and smoking 30 minutes before sampling.
[0118] 2. Genetic testing
[0119] After adding the sample to be tested, negative quality control product, and positive quality control product to the PCR reaction tube in parallel, the test is performed on the fluorescent PCR instrument, the FAM and TexasRed fluorescent signals are collected, and the PCR reaction program is set to perform the amplification reaction. The PCR reaction program is shown in Table 6:
[0120] Table 6 PCR reaction program
[0121]
[0122] 3. Interpretation of results
[0123] After the PCR reaction is completed, the test results are analyzed separately by the amplification curve and melting curve of the analysis system. When the positive control group has FAM and TexasRed fluorescence amplification curves and corresponding melting peaks, the negative control group has no amplification curve and melting peak, the test sample has an amplification curve and melting peak, and the internal reference gene signal of the TexasRed channel has an obvious melting peak signal at 73℃±1℃, the experiment is judged to be successful; if not, it is necessary to re-test. After the experiment is judged to be successful, the A2M rs669, FXII rs1801020 and ZBTB46 rs76484331 gene loci are typed according to the experimental results in Table 7.
[0124] Table 7 Test result judgment value setting
[0125]
[0126] Note: Tm value is the temperature corresponding to the peak of the melting curve.
[0127] 4. Assessment of risk of hemorrhagic transformation
[0128] The risk score Logit (P) of "whether hemorrhagic transformation occurs" for each AIS patient is predicted based on the admission NIHSS score and the genotyping of A2M, FXII, and ZBTB46:
[0129] Logit (P) = -3.68 + 1.92 × A2M rs669 (AA or AG = 1, GG = 0) + 0.3 × FXII rs1801020 (AG or GG = 1, AA = 0) + 1.88 × ZBTB46 rs76484331 (GT or TT = 1, GG = 0) + 1.3 × admission NIHSS score. Then according to the formula: P = e Logit(P) / (1+e Logit(P) ), the probability of hemorrhagic transformation of AIS patients treated with rt-PA thrombolytic therapy was calculated. P>0.289 was a high-risk group for hemorrhagic transformation, and it was recommended to reduce the dosage of rt-PA or switch to other thrombolytic drugs; P<0.289 was a low-risk group for hemorrhagic transformation, and the standard dose was used.
[0130] Example 6 Accuracy Test
[0131] According to the method of Example 5, the 30 patient samples (P1-P30) collected were tested synchronously with the positive quality control products and the negative quality control products, and the three types of each SNP site (wild type, heterozygous mutant type, homozygous mutant type) were detected at least once. The test results were interpreted according to the method of Table 7, and the interpretation results are shown in Table 8. The detection signals of the positive quality control products FAM and TexasRed both formed a logarithmic amplification "S" curve, and the negative quality control products had no amplification curve and melting curve. At the same time, each sample was tested by Sanger first-generation sequencing and compared with the detection method of the present application. The consistency rate between the detection method of the present invention and the Sanger first-generation sequencing results was 100%, which shows that the detection accuracy of the kit of the present invention is relatively high. See the attached Figure 4 , 5 , which are the amplification curve and melting curve of samples P1 and P2 respectively.
[0132] Compared with the prior art, the present invention adjusts the types and proportions of primers and probes, and adjusts the addition amount and concentration of probes and mediator sequences, thereby avoiding the influence of fluorescent probes on the melting curve results of the same fluorescent channel when fluorescent probes and melting curve detection methods are used simultaneously in the prior art, and at the same time avoids the high fluorescent background signal caused by the combination of P1 cut off and the mediator sequence during annealing and extension, resulting in false positives or false negatives, and large errors in the detection results. In the melting curve stage of the present invention, the Taqman fluorescent probe has been consumed and will not affect the melting curve results. At the same time, by adjusting the amplification reaction process, the 3' end of the mediator probe is modified with a dideoxygenase during annealing and extension, the probe is blocked, the extension reaction of the probe is prevented, the influence of the fluorescent signal is avoided, and the detection accuracy is improved.
[0133] Table 830 Sample Test Results
[0134]
[0135]
[0136] Example 7 Detection limit test
[0137] The kit method in Example 5 was selected to collect clinical samples for detection limit test. The test sample of this kit is oral mucosal exfoliated cells. P1 and P2 samples in Table 8 were selected to collect and wash oral mucosal exfoliated cells. After cell counting, the cells were diluted to 400 cells / μL, 300 cells / μL, 200 cells / μL, 100 cells / μL and 50 cells / μL with physiological saline for five different concentration gradients for detection. Each sample was repeated 20 times, and the acceptance standard was 95% positive detection rate. The test results are shown in Tables 9-10: When the cell sample concentration is greater than or equal to 200 cells / μL, the positive detection rate reaches 100%; when the sample concentration is 100 cells / μL, the positive detection rate reaches more than 95%; when the cell concentration is 50 cells / μL, the positive detection rate is lower than the detection limit requirement. The results show that the minimum detection limit concentration of oral mucosal exfoliated cells of this kit is 100 cells / μL.
[0138] Table 9 Detection limit test results of sample P1
[0139]
[0140] Table 10 Detection limit test results of sample P2
[0141]
[0142] In summary, according to the design of the present invention, a PCR primer set of the corresponding gene of the kit is prepared, the NIHSS score of the patient at admission is counted, the typing of the gene related to hemorrhagic transformation of rt-PA is detected, the probability of hemorrhagic transformation is calculated, and the risk of hemorrhagic transformation of AIS patients is determined by comparing with the cut-off value of the model. According to the patient's risk size, the appropriate rt-PA medication regimen is selected, and the occurrence of hemorrhagic transformation is ultimately reduced, and the patient's poor prognosis is improved.
[0143] The above is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments. For those skilled in the art, any modification, equivalent replacement, improvement, etc. made without departing from the technical concept of the present invention should be included in the protection scope of the present invention.
Claims
1. Use of a kit in establishing a risk assessment model for predicting rt-PA thrombolytic hemorrhagic transformation in acute ischemic stroke, characterized in that: The kit amplifies three gene site polymorphisms of A2M rs669, FXII rs1801020 and ZBTB46rs76484331 and an internal reference gene in the same closed reaction tube, and the risk assessment model is constructed in the following manner: according to the admission NIHSS score and the genotyping of A2M, FXII and ZBTB46, the risk score Logit (P) of "whether hemorrhagic transformation occurs" is predicted; Logit (P) = -3.68 + 1.92 × A2M rs669 (AA or AG = 1, GG = 0) + 0.3 × FXII rs1801020 (AG or GG = 1, AA = 0) + 1.88 × ZBTB46 rs76484331 (GT or TT = 1, GG = 0) + 1.3 × admission NIHSS score; Then according to the formula: P = e Logit(P) / (1+e Logit(P) ), the probability of hemorrhagic transformation of AIS patients treated with rt-PA thrombolytic therapy was calculated; if P>0.289, the patient was at high risk of hemorrhagic transformation and needed to reduce the dosage of rt-PA or switch to other thrombolytic drugs; if P<0.289, the patient was at low risk of hemorrhagic transformation and should be given the standard dose.
2. The use according to claim 1, characterized in that The risk assessment model is constructed in the following steps: (1) Sample collection: Oral mucosal exfoliated cells from patients with acute ischemic stroke who require rt-PA thrombolytic therapy were scraped with disposable sterile swabs as samples to be tested; (2) Genetic testing: Add the sample to be tested into a PCR tube containing the reaction solution, set up a positive control group and a negative control group for testing, collect FAM and TexasRed fluorescence signals, and set up a PCR reaction program for amplification reaction; (3) Result interpretation: After the PCR amplification reaction is completed, the result is judged based on the collected fluorescence signal amplification curve and melting peak Tm value; when the positive control group has FAM and TexasRed fluorescence amplification curves and corresponding melting peaks, the negative control group has no amplification curve and melting peak, the test sample has an amplification curve and melting peak, and the internal reference gene signal of the TexasRed channel has an obvious melting peak signal at 73℃±1℃, the experiment is judged to be successful, and the A2M rs669, FXII rs1801020 and ZBTB46rs76484331 gene loci are typed; if not, re-testing is required; (4) Construction of a hemorrhagic transformation risk assessment model: For each AIS patient, the risk score Logit (P) of "whether hemorrhagic transformation will occur" is predicted based on the admission NIHSS score and the genotyping of A2M, FXII, and ZBTB46: Logit (P) = -3.68 + 1.92 × A2M rs669 (A allele = 1, G allele = 0) + 0.3 × FXIIrs1801020 (G allele = 1, A allele = 0) + 1.88 × ZBTB46 rs76484331 (T allele = 1, G allele = 0) + 1.3 × admission NIHSS score; then according to the formula: P = e Logit(P) / (1+e Logit(P) ), the probability of hemorrhagic transformation of AIS patients treated with rt-PA thrombolytic therapy was calculated; if P>0.289, the patient was at high risk of hemorrhagic transformation and needed to reduce the dosage of rt-PA or switch to other thrombolytic drugs; if P<0.289, the patient was at low risk of hemorrhagic transformation and should be given the standard dose.
3. A gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment, characterized in that: The kit is used for jointly detecting polymorphisms of three gene loci, A2M rs669, FXII rs1801020 and ZBTB46rs76484331, and an internal reference gene in the same closed reaction tube. The kit comprises a primer set sequence, which comprises a total of 8 primer sequences, 2 Taqman fluorescent probes, 5 3'-end blocked mediator probes and 2 fluorescently labeled mediator sequences; the primer set sequence is as follows: Primer set sequences for detecting A2M rs669: Upstream primer: 5'-CCAGTGTTGAGATAGCCAAT-3', as shown in SEQ ID No. 1; Downstream primer: 5'-GCTGTGGAGAGCAGAATATG-3', as shown in SEQ ID No. 2; Wild-type Taqman probe: 5'-FAM-ACTCCAGAGATCA-MGB modified-3', shown in SEQ ID No. 3; Mutant Taqman probe: 5'-TexasRed-ACTCCAGAGGTCA-MGB modified-3', shown in SEQ ID No. 4; Primer set sequences for detecting FXII rs1801020: Upstream primer: 5'-AAAGTGTTGACTCCAAGCTC-3', shown in SEQ ID No.5; Downstream primer: 5'-GATCTGGACTCCTGGATAGG-3', shown in SEQ ID No.6; Wild-type mediator probe: 5'- GGGAGAAGTGTCAC AGAGCCCTCATGGCATCC-dideoxy modification-3', shown in SEQ ID No. 7; Mutation-mediated probe: 5'- GTGGGGAGAAGT AGAGCCCTCATGGCGTCC-dideoxy modified-3', shown in SEQ ID No. 8; Primer set sequences for detecting ZBTB46 rs76484331: Upstream primer: 5'-GAACAGAATCCCACATACGG-3', shown in SEQ ID No.9; Downstream primer: 5'-TTCTTCAAGCGTGAGGGATG-3', shown in SEQ ID No.10; Wild-type mediator probe: 5'- AGATCGTGAGGGCCA CAGTGTA+GGTCATTTAACC-dideoxy modification-3', as shown in SEQ ID No.11; Mutation-mediated probe: 5'- GAAGAGATCGTGAGCCA CAGTGTATGTCATTTAACCG-dideoxy modification-3', shown in SEQ ID No.12; The sequences of the internal reference β-actin primer probe are as follows: Upstream primer: 5'-ACCAGATGTGTTCCGTGTCC-3', as shown in SEQ ID No. 13; Downstream primer: 5'-TGCTCGTGTTCATCAAAGTCT-3', as shown in SEQ ID No. 14; Intermediate probe: 5'- CACAGGAAGAGATCG CCTTCGTGCTTGTGATGTCTTC—dideoxy modification-3′, as shown in SEQ ID No.
15.
4. A gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment as claimed in claim 3, characterized in that: The kit simultaneously uses a fluorescent probe method combined with a fluorescent probe melting curve method to detect the level of hemorrhagic transformation in a sample.
5. A gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment as claimed in claim 4, characterized in that: The A2M rs669 gene locus was detected by Taqman fluorescent probe method, and the FXII rs1801020, ZBTB46rs76484331 and β-actin internal reference gene loci were detected by fluorescent probe melting curve method.
6. A gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment as claimed in claim 3, characterized in that: The two mediator sequences are two mediator primer docking sequences for mediator probe binding, and their sequences are: SStarget-Probe1: 5'-FAM-ACCAGAGATACCTTGACACTTCTCCCACTCTGGT-BHQ1 modified-3', as shown in SEQ ID No. 16; SStarget-Probe2: 5′-TexasRed-ACGAGCTGCCCTCACGATCTCTTCCTGTGAGCTCGT–BHQ2-3′, as shown in SEQ ID No.
17.
7. A gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment as claimed in claim 6, characterized in that: The FXII rs1801020 detection introduces the intermediate primer docking sequence SStarget-Probe1; the ZBTB46rs76484331 and β-actin internal reference gene detection introduces the intermediate primer docking sequence SStarget-Probe2.
8. A gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment based on any one of claims 3 to 7, characterized in that: The kit also includes a PCR reaction solution, a negative quality control product and a positive quality control product.
9. A gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment as claimed in claim 8, characterized in that: The PCR reaction solution comprises PCR buffer, dNTPs, MgCl2, Taq enzyme, sodium dodecyl sulfate, polyethylene glycol octylphenyl ether, a primer set and ultrapure water.
10. A gene polymorphism detection kit for predicting the risk of hemorrhagic transformation after rt-PA treatment as claimed in claim 8, characterized in that: The concentration of each component in the PCR reaction solution is as follows:
Citation Information
Patent Citations
Multiplex fluorescence melting curve based PCR detection method
CN106191214A
A method for detecting a target nucleic acid sequence
CN108823287A
Method for detecting nucleotide fragment deficiencies and kit
CN111100908A
Gene polymorphism rapid detection primer group and kit for guiding Parkinson's disease medication
CN116837089A
